MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro

HER2-positive (HER2 +) breast cancer patients that do not respond to targeted treatment have a poor prognosis. The effects of targeted treatment on endogenous microRNA (miRNA) expression levels are unclear. We report that responsive HER2 + breast cancer cell lines had a higher number of miRNAs with...

Descripción completa

Detalles Bibliográficos
Autores principales: Normann, Lisa Svartdal, Aure, Miriam Ragle, Leivonen, Suvi-Katri, Haugen, Mads Haugland, Hongisto, Vesa, Kristensen, Vessela N., Mælandsmo, Gunhild Mari, Sahlberg, Kristine Kleivi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149698/
https://www.ncbi.nlm.nih.gov/pubmed/34035375
http://dx.doi.org/10.1038/s41598-021-90385-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149698/
https://www.ncbi.nlm.nih.gov/pubmed/34035375
http://dx.doi.org/10.1038/s41598-021-90385-2

Ejemplares similares